Contents
Download PDF
pdf Download XML
780 Views
661 Downloads
Share this article
Review Article | Volume:1 Issue 2 (None, 2011) | Pages 21 - 30
Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark
Under a Creative Commons license
Open Access
Published
June 25, 2010
Abstract
The safety and efficacy of coronary stents utilised for treatment of ischaemic heart disease have been extensively evaluated. In comparison with bare metal stents, first-generation drug-eluting stents more than halved the need for target lesion revascularisation (TLR). However, the long-term safety has been questioned as the first-generation drug-eluting stents seemed to be associated with a small, but increased, risk of (very) late stent thrombosis. The latter may be related to an inflammatory reaction caused by the polymer used for drug release control. The second-generation zotarolimus- eluting Endeavor® stent was believed to represent a safer alternative. We present an overview of our results from a large randomised trial and a large registry, both of which compared clinical outcomes with the Endeavor® and the first-generation sirolimus-eluting Cypher® stent. Both studies indicated that the Endeavor® stent had higher risks of adverse outcomes. We discuss these data in the light of the current available data from other randomised comparisons of these two drug-eluting stents.
Keywords
Recommended Articles
Research Article
Psychological Disturbances and Quality of Life Among Obese Infertile Women in Amalapuram
...
Published: 14/02/2025
Download PDF
Research Article
Study of GATA3 Expression in Urothelial Cell Tumors
...
Published: 11/02/2025
Download PDF
Research Article
Correlation of Platelet Indices with Thrombocytosis: A Clinicopathological Study in a Tertiary Care Hospital
Published: 30/06/2023
Download PDF
Research Article
Fixation of pertrochanteric fracture with proximal femoral nail in adults
Published: 20/09/2018
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.